Secondary patenting of branded pharmaceuticals: A case study of how patents on two HIV drugs could be extended for decades

Health Affairs

Volumn 31, Issue 10, 2012, Pages 2286-2294

  Amin, Tahir ^a   Kesselheim, Aaron S ^b  

^a Initiative for Medicines Access and Knowledge   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR;

ARTICLE; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MARKETING; PATENT; STANDARD; UNITED STATES;

DATABASES, FACTUAL; DRUG COMBINATIONS; DRUG INDUSTRY; ECONOMIC COMPETITION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LOPINAVIR; PATENTS AS TOPIC; RITONAVIR;

EID: 84870779105     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2012.0107     Document Type: Article

References (37)

1. Outterson K. Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets. Yale J Health Policy Law Ethics. 2005;5(1):193-291.
2. Shrank WH, Choudhry NK, Agnew-Blais J, Federman AD, Liberman JN, Liu J, et al. State generic substitution laws can lower drug outlays under Medicaid. Health Aff (Millwood). 2010;29(7):1383-90.
3. Thomas J.R. Patent "evergreening": issues in innovation and competition [Internet]. Washington (DC): Congressional Research Service; 2009 Nov 13 [cited 2012 Aug 21]. Available from: http://ipmall.info/ hosted_resources/crs/R40917_ 091113.pdf
4. Astra Aktiebolag v. Andrx Pharmaceuticals, 222 F. Supp. 2d 423 (S.D.N.Y. 2002). 5 Schering Corp. v. Geneva Pharmaceutical, 339 F. 3d 1373 (FCCA 2003).
5. Schering Corp. v. Geneva Pharmaceutical, 339 F. 3d 1373 (FCCA 2003).
6. Kesselheim AS, Mello MM. Medicalprocess patents-monopolizing the delivery of health care. N Engl J Med. 2006;355(19):2036-41.
7. Wyllie MG. Evergreening: there's life in the old drug yet. BJU Int. 2005; 95(9):1359-60.
8. Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, Delapp D, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improved medication adherence for chronic conditions. Arch Intern Med. 2006; 166(3):332-7.
9. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007; 298(1):61-9.
10. Kesselheim A, Fischer M, Avorn J. Extensions of intellectual property rights and delayed adoption of generic drugs: effects on Medicaid spending. Health Aff (Millwood). 2006;25:1637-47.
11. Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421-9.
12. Soumerai S. Unintended outcomes of Medicaid drug cost-containment policies on the chronically mentally ill. J Clin Psychiatry. 2003; 64(SUPPL 17):19-22.
13. Agranat I, Wainschtein SR. The strategy of enantiomer patents of drugs. Drug Discov Today. 2010; 15(5-6):163-70.
14. Faunce T, Vines T, Gibbons H. New forms of evergreening in Australia: misleading advertising, enantiomers, and data exclusivity: Apotex v Servier and Alphapharm v Lundbeck. J Law Med 2008; 16(2):220-32.
15. Elliott G. Basics of US patents and the patent system. AAPS J. 2007; 9(3):E317-24.
16. To access the Appendix, click on the Appendix link in the box to the right of the article online
17. Food and Drug Administration. Orange book: approved drug products with therapeutic equivalence evaluations [Internet]. Silver Spring (MD): FDA; [last updated 2012 Jun 13; cited 2012 Aug 22]. Available from: http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm
18. European Patent Office. Espacenet patent search [Internet]. Munich: The Office; [last updated 2012 Mar 14; cited 2012 Aug 22]. Available from: http://worldwide.espacenet.com
19. US Patent and Trademark Office. Patent application information retrieval [Internet]. Alexandria (VA): USPTO; [cited 2012 Aug 22]. Available from: http://portal.uspto.gov/ external/portal/pair
20. Glaser BG, Strauss AL. The discovery of grounded theory: strategies for qualitative research. Chicago (IL): Aldine Publishing Company; 1967.
21. Constas MA. Qualitative data analysis as a public event: the documentation of category development procedures. Am Educ Res J. 1992; 29:253-66.
22. Kesselheim AS, Mello MM, Studdert DM. Strategies and practices in offlabel marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med 2011; 8(4):e1000431.
23. The nine patents are numbers 5,484,801; 5,559,158; 5,948,436; 6,232,333; 6,458,818; 6,521,651; 6,911,214; 7,141,593; and 7,432,294
24. Initiative for Medicines, Access, and Knowledge. Statement of case of the opponent [Internet]. Lewes (DE): I-MAK; 2007 Aug 16 [cited 2012 Aug 22]. Available from: http:// www.i-mak.org/storage/I-MAK %20Pregrant%20Opp%20339%20 MUM%202006%20.pdf
25. Initiative for Medicines, Access, and Knowledge. Statement of the opponent in reply to the applicant's response filed under Rule 55(4). [Internet]. Lewes (DE): I-MAK; 2009 Feb 16 [cited 2012 Aug 22]. Available from: http://www.i-mak.org/ storage/I%20MAK%20Statement %20of%20Reply%20339 %20MUM%20NP%202006.pdf
26. Dias L, Al-Razzak L, Eiden E, Gao R, Kaul D, Lechuga-Ballesteros D, et al. Physical and oral dog bioavailability evaluation of ABT-538: PVP coprecipitates. Pharm Res. 1996; 13(9):S351.
27. Correa C (University of Buenos Aires). Guidelines for the examination of pharmaceutical patents: developing a public health perspective [Internet]. Geneva: International Centre for Trade and Sustainable Development; 2007 Jan [cited 2012 Aug 22]. (Working Paper). Available from: http://ictsd.org/downloads/2008/04/correa_pharmaceuticalpatents-guidelines.pdf
28. Parker S, Mooney K. Is "evergreening" a cause for concern? A legalperspective. J Commer Biotechnol. 2007;13:235-43.
29. Berndt ER, Cockburn IM, Grépin KA. The impact of incremental innovation in biopharmaceuticals: drug utilization in original and SUPPLemental indications. Pharmacoeconomics. 2006; 24(SUPPL 2):69-83.
30. Klein CE, Chiu YL, Awni W, Zhu T, Heuser RS, Doan T, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr. 2007;44(4): 401-10.
31. Hemphill CS, Sampat BN. Evergreening, patent challenges, and effective market life in pharmaceuticals. J Health Econ. 2012; 31(2):327-39.
32. Kesselheim AS, Murtagh L, Mello MM. "Pay for delay" settlements of disputes over pharmaceutical patents. N Engl J Med. 2011; 365(15):1439-45.
33. Amin T, Rajkumar R, Radhakrishnan P, Kesselheim AS. Expert review of drug patent applications: improving health in the developing world. Health Aff (Millwood). 2009;28(5):w948-56. DOI: 10.1377/hlthaff.28.5.w948.
34. Burchfiel K. USPTO post-grant opposition costs-a forum conveniens for invalidity disputes. USPTO Post-Grant Oppositions [blog on the Internet]. 2012 May 20 [cited 2012 Aug 22]. Available from: http://usptopost-grant.com/2012/05/20/uspto-post-grant-opposition-costs-aforum-conveniens-for-invaliditydisputes
35. Crouch D. Making pre-grant submissions more effective. Patently-O [blog on the Internet]. 2012 Jul 19 [cited 2012 Aug 7]. Available from http://www.patentlyo.com/patent/2012/07/pre-grant-submissions.html?utm_source=feedburner& utm_medium=email&utm_ campaign=Feed%3A+PatentlyO +%28Dennis+Crouch%27s +Patently-O%29
36. Health Canada. Guidance document: patented medicines (notice of compliance) regulations (revised 2012) [Internet]. Ottawa: Health Canada; 2012 Apr 2 [cited 2012 Aug 22]. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/patmedbrev/pmreg3_mbreg3-eng.php
37. KSR International v. Teleflex (550 U.S. 398, 2007).